A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats

European Journal of Pharmacology

Volumn 616, Issue 1-3, 2009, Pages 340-345

  Henriksen, Kim ^a   Byrjalsen, Inger ^a   Nielsen, Rasmus H ^a   Madsen, Andreas N ^a   Larsen, Leif K ^a   Christiansen, Claus ^b   Beck Nielsen, Henning ^c   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Balaglitazone; Bone formation; Diabetes; Oedema; Oral glucose tolerance test; Pioglitazone

Indexed keywords

BALAGLITAZONE; INSULIN; OSTEOCALCIN; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; GLYCEMIC CONTROL; INSULIN RELEASE; LIPID STORAGE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RAT; WATER RETENTION; WEIGHT GAIN;

ADIPOGENESIS; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; BONE AND BONES; BONE RESORPTION; DIET; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MALE; MUSCLES; OBESITY; OSTEOGENESIS; PPAR ALPHA; QUINAZOLINES; RATS; THIAZOLIDINEDIONES; WATER;

EID: 67651121966     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.06.051     Document Type: Article

References (39)

1. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., and Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146 (2005) 1226-1235
2. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 (2005) 244-251
3. Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., Elbrecht A., Johnson B.A., Zhou G., Doebber T.W., Biswas C., Parikh M., Sharma N., Tanen M.R., Thompson G.M., Ventre J., Adams A.D., Mosley R., Surwit R.S., and Moller D.E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 17 (2003) 662-676
4. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., Rufer A., Ruf A., Kuhn B., Marki H.P., Mizrahi J., Sebokova E., Niesor E., and Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma- coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20 (2006) 809-830
5. Deeg M.A., and Tan M.H. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR. Res. (2008) 520465
6. Diep Q.N., El M.M., Cohn J.S., Endemann D., Amiri F., Virdis A., Neves M.F., and Schiffrin E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II- infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105 (2002) 2296-2302
7. Duval C., Chinetti G., Trottein F., Fruchart J.C., and Staels B. The role of PPARs in atherosclerosis. Trends Mol. Med. 8 (2002) 422-430
8. Eguchi K., Tomizawa H., Ishikawa J., Hoshide S., Numao T., Fukuda T., Shimada K., and Kario K. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens. Res. 30 (2007) 23-30
9. Einstein M., Akiyama T.E., Castriota G.A., Wang C.F., McKeever B., Mosley R.T., Becker J.W., Moller D.E., Meinke P.T., Wood H.B., and Berger J.P. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. Mol. Pharmacol. 73 (2008) 62-74
10. Froment P., and Touraine P. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR. Res. (2006) 73986
11. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., and Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46 (1997) 433-439
12. Glintborg D., Hojlund K., Andersen M., Henriksen J.E., Beck-Nielsen H., and Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 31 (2008) 328-334
13. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., and Reid I.R. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab 92 (2007) 1305-1310
14. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., and Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11 (2005) 861-866
15. Khan E., and bu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J. Lab Clin. Med. 142 (2003) 29-34
16. Kintscher U., Goetze S., Wakino S., Kim S., Nagpal S., Chandraratna R.A., Graf K., Fleck E., Hsueh W.A., and Law R.E. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol. 401 (2000) 259-270
17. Knouff C., and Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25 (2004) 899-918
18. Larsen P.J., Jensen P.B., Sorensen R.V., Larsen L.K., Vrang N., Wulff E.M., and Wassermann K. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 52 (2003) 2249-2259
19. Larsen P.J., Lykkegaard K., Larsen L.K., Fleckner J., Sauerberg P., Wassermann K., and Wulff E.M. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur. J. Pharmacol. 596 (2008) 173-179
20. Lazarenko O.P., Rzonca S.O., Suva L.J., and Lecka-Czernik B. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38 (2006) 74-84
21. Lecka-Czernik B., Gubrij I., Moerman E.J., Kajkenova O., Lipschitz D.A., Manolagas S.C., and Jilka R.L. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J. Cell. Biochem. 74 (1999) 357-371
22. Levin B.E., Dunn-Meynell A.A., Balkan B., and Keesey R.E. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am. J. Physiol 273 (1997) R725-R730
23. Li M., Pan L.C., Simmons H.A., Li Y., Healy D.R., Robinson B.S., Ke H.Z., and Brown T.A. Surface- specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 39 (2006) 796-806
24. Loke Y.K., Singh S., and Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: systematic review and meta-analysis. CMAJ (2008)
25. McDonough A.K., Rosenthal R.S., Cao X., and Saag K.G. The effect of thiazolidinediones on BMD and osteoporosis. Nat. Clin. Pract. Endocrinol. Metab 4 (2008) 507-513
26. Rahman S., Ismail A.A., Ismail S.B., Naing N.N., and bdul Rahman A.R. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur. J. Clin. Pharmacol. 63 (2007) 733-741
27. Rosen C.J. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. N. Engl. J. Med. 357 (2007) 844-846
28. Rosen C.J. Sugar and bone: a not-so sweet story. J. Bone Miner. Res. 23 (2008) 1881-1883
29. Schaller S., Henriksen K., Hoegh-Andersen P., Sondergaard B.C., Sumer E.U., Tanko L.B., Qvist P., and Karsdal M.A. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay. Drug Dev. Technol. 3 (2005) 553-580
30. Schaller S., Henriksen K., Sveigaard C., Heegaard A.M., Helix N., Stahlhut M., Ovejero M.C., Johansen J.V., Solberg H., Andersen T.L., Hougaard D., Berryman M., Shiodt C.B., Sorensen B.H., Lichtenberg J., Christophersen P., Foged N.T., Delaisse J.M., Engsig M.T., and Karsdal M.A. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Miner. Res. 19 (2004) 1144-1153
31. Schwartz A.V. TZDs and Bone: A Review of the Recent Clinical Evidence. PPAR. Res. (2008) 297893 2008
32. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
33. Song J., Knepper M.A., Hu X., Verbalis J.G., and Ecelbarger C.A. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J. Pharmacol. Exp. Ther 308 (2004) 426-433
34. Sorensen M.G., Henriksen K., Schaller S., and Karsdal M.A. Biochemical markers in preclinical models of osteoporosis. Biomarkers 12 (2007) 266-286
35. Soroceanu M.A., Miao D., Bai X.Y., Su H., Goltzman D., and Karaplis A.C. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J. Endocrinol. 183 (2004) 203-216
36. Takada I., Suzawa M., Matsumoto K., and Kato S. Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts. Ann. N.Y. Acad. Sci. 1116 (2007) 182-195
37. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341-367
38. Yokoyama J., Sutoh N., Higuma T., Horiuchi D., Katoh C., Yokota T., Echizen T., Sasaki S., Hanada H., Osanai T., and Okumura K. Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22 (2007) 146-151
39. Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H.R., and Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J. Clin. Endocrinol. Metab 89 (2004) 1140-1145